OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates
Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...
OBI Pharma
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...
OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC
Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...